Previous Statements by MYGN
» Myriad Genetics Inc. F2Q10 Earnings Conference Call
» Myriad Genetics, Inc F4Q09 (Qtr End 06/30/09) Earnings Call Transcript
» Myriad Genetics F3Q09 (Qtr End 03/31/09) Earnings Call Transcript
Those who thought we were ready to break down look foolish again.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
Jefferies lowered its price target to $20 on Myriad Genetics (MYGN) stock this morning saying that 'hereditary cancer cracks are emerging.'